Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Omaha, Nebraska 68198


Purpose:

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating children who have relapsed acute lymphocytic leukemia.


Study summary:

OBJECTIVES: - Determine the efficacy of autologous peripheral blood stem cell (PBSC) transplantation for marrow reconstitution after high-dose carmustine, cytarabine, etoposide, and cyclophosphamide in children with relapsed acute lymphocytic leukemia. - Determine the dose effect of autologous PBSC on engraftment in this patient population. OUTLINE: Patients receive chemotherapy mobilization comprising cytarabine IV every 12 hours on days 1-5. When blood counts recover, autologous peripheral blood stem cells (PBSC) are harvested and selected for mononuclear cells, granulocyte-macrophage colony-forming units, and CD34+ cells. Patients receive preparative regimen comprising carmustine IV on days -8 and -3, cytarabine IV every 12 hours and etoposide IV every 12 hours on days -7 to -4, and cyclophosphamide IV on days -2 and -1. PBSC are reinfused on day 0. Patients receive filgrastim (G-CSF) or sargramostim (GM-CSF) beginning after PBSC transplantation. Male patients undergo radiotherapy to the testes before transplantation. Patients with a history of CNS leukemia undergo craniospinal irradiation before transplantation. Patients are followed at 100 days, 6 months, and 1 year. PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study within 5 years.


Criteria:

DISEASE CHARACTERISTICS: - Diagnosis of acute lymphoblastic leukemia - Pathologic evidence of relapse in marrow, CNS, or testes - In second or later complete remission - Ineligible for allogeneic transplantation: - No suitable allogeneic donor (sibling or family donor or unrelated donor with no more than 1 HLA-A or -B antigen mismatch and HLA-DR identical) OR - Ineligible for preparative regimen including total-body irradiation - Peripheral blood stem cell collection feasible: - Patient size generally at least 8 kg - Able to place central venous catheter - Patient cooperative PATIENT CHARACTERISTICS: Age: - 1 to 19 Performance status: - Not moribund Life expectancy: - No severe limits from disease other than leukemia Hepatic: - Bilirubin no greater than 3 times normal for age - AST and/or GGT no greater than 3 times normal for age - No evidence of hepatic synthetic dysfunction Renal: - GFR at least 50% of normal based on Glofil study or 12-hour creatinine clearance Cardiovascular: - Cardiac contractility normal on echocardiogram Pulmonary: - FVC and FEV_1 with or without DLCO at least 50% predicted Other: - No significant active infection - HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics Chemotherapy - See Disease Characteristics Endocrine therapy - Not specified Radiotherapy - See Disease Characteristics Surgery - Not specified


NCT ID:

NCT00002638


Primary Contact:

Study Chair
Bruce G. Gordon, MD
University of Nebraska


Backup Contact:

N/A


Location Contact:

Omaha, Nebraska 68198
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 21, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.